Market Spotlight: Sarcoma
|出版日期||內容資訊||英文 57 Pages
|焦點市場分析:肉瘤 Market Spotlight: Sarcoma|
|出版日期: 2019年12月31日||內容資訊: 英文 57 Pages||
This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, probability of success, recent events and analyst opinion, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2017, there were approximately 413,300 incident cases of sarcoma worldwide, and forecasts that number to increase to 485,100 incident cases by 2026. Worldwide, the majority of sarcoma cases were soft tissue and other extraosseous sarcomas (83%), while a smaller proportion were osteosarcomas and other malignant bone tumors (17%).
The approved drugs in the sarcoma space focus on a wide variety of targets. The majority of approved drugs are administered via the intravenous route, with two products being available in oral formulations.
The majority of industry-sponsored drugs in active clinical development for sarcoma are in Phase II, with only one drug in the NDA/BLA stage.
Therapies in development for sarcoma focus on a wide variety of targets. The majority of these therapies are administered via the oral and intravenous routes, with the remainder being intraocular/subretinal/subconjunctival, intradermal, intramuscular, intraarterial, intratumoral, and topical formulations.
High-impact upcoming events in the sarcoma space comprise topline Phase II trial results for ADP-A2M4CD8 and an expected PDUFA date for tazemetostat.
The overall likelihood of approval of a Phase I sarcoma asset is 10.7%, and the average probability a drug advances from Phase III is 50%. Drugs, on average, take 9.6 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
There have been 17 licensing and asset acquisition deals involving sarcoma drugs during 2014-19. The largest deal during the period was the $1,150m strategic collaboration and licensing agreement signed in 2014 between Adaptimmune and GlaxoSmithKline to develop and commercialize Adaptimmune's NY-ESO-1 program.
The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for sarcoma have been in the early and mid-phases of development, with 89% of trials in Phase I-II, and only 11% in Phase III-IV.
The US has a substantial lead in the number of sarcoma clinical trials globally. France leads the major EU markets, while Israel has the top spot in Asia
Clinical trial activity in the sarcoma space is dominated by completed trials. Merck & Co and Novartis have the highest number of completed clinical trials for sarcoma, with 19 trials each.
Merck & Co leads industry.